| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
(E)-Naringenin chalcone is an orally active anti-allergic agent. It also has antioxidant and anti-inflammatory activities. It can improve adipocyte functions. It suppresses allergic asthma by inhibiting the type-2 function of CD4 T cells.
|
|---|---|
| ln Vitro |
(E)-Naringenin chalcone (25-125 μg/mL, 10 min) suppresses the release of histamine from rat peritoneal mast cells with an IC50 value of 68 μg/mL[1]. (E)-Naringenin chalcone (25–50 μM, 8 days) increases the synthesis of adiponectin, which enhances the functions of adipocytes (3T3–L1)[2]. In NIH-3T3 cells, (E)-Naringenin chalcone (25–100 μM, 24 h) increases PPARγ activity[2]. (E)-Naringenin chalcone (0-200 μM 24 h) suppresses LPS-stimulated RAW 264 macrophages' ability to produce TNF-alpha, MCP-1, and nitric oxide (NO)[4].
In vitro, (E)-Naringenin chalcone has antioxidant and anti-inflammatory activities. It can improve adipocyte functions. It suppresses allergic asthma by inhibiting the type-2 function of CD4 T cells. It shows potential for allergy and inflammation research. |
| ln Vivo |
In mice with type I allergies, (E)-Naringenin chalcone (0.8 mg/kg, oral treatment) exhibits anti-allergic properties[1]. In allergic airway inflammatory mice, (E)-Naringenin chalcone (0.8 mg/kg, oral treatment) reduces allergic asthma by preventing CD4 T cells from performing their type-2 function[3].
In vivo, (E)-Naringenin chalcone is an orally active anti-allergic agent. At 0.8 mg/kg, oral administration suppresses allergic asthma by inhibiting the type-2 function of CD4 T cells in allergic airway inflammatory mice. It has antioxidant and anti-inflammatory activities. |
| Enzyme Assay |
Cell-free assays for (E)-Naringenin chalcone: antioxidant activity is measured using DPPH, ABTS, and FRAP assays. Anti-inflammatory activity is assessed by measuring inhibition of COX-2 or LOX enzyme activities. Allergic response is evaluated by measuring histamine release or IgE binding in cell-free systems.
|
| Cell Assay |
Cellular assays for (E)-Naringenin chalcone: CD4 T cells are isolated and treated with (E)-Naringenin chalcone at concentrations of 0.1-100 µM for 24-72 hours. Type-2 cytokine production (IL-4, IL-5, IL-13) is measured by ELISA. T cell proliferation is measured by CFSE dilution. Adipocytes are treated to assess adipocyte function and lipid metabolism. Cell viability is measured by MTT assay.
|
| Animal Protocol |
Animal/Disease Models: Mouse type I allergic model[1]
Doses: 0.8 mg/kg Route of Administration: Oral administration Experimental Results: Inhibited the ear-swelling response, with the inhibitory ratio of 46.7%. Animal/Disease Models: Allergic airway inflammation induced in mice[3] Doses: 0.8 mg/kg Route of Administration: Oral administration, daily Experimental Results: diminished cell numbers of the infiltrating leukocyte and eosinophils. diminished Muc5ac and gob-5 expression in the lungs. In vivo animal studies for (E)-Naringenin chalcone: allergic airway inflammatory mouse models are used. Animals are administered (E)-Naringenin chalcone orally at 0.8 mg/kg. Airway inflammation, eosinophil infiltration, and cytokine levels are assessed. Type-2 CD4 T cell function is evaluated in lung tissues. |
| ADME/Pharmacokinetics |
Pharmacokinetic properties of (E)-Naringenin chalcone: as a small molecule (molecular weight 272.26), it may have good oral bioavailability. It is likely metabolized in the liver and excreted via the kidneys. Tissue distribution and elimination pathways require further investigation.
|
| Toxicity/Toxicokinetics |
Toxicity of (E)-Naringenin chalcone: comprehensive toxicity data are limited. As a natural flavonoid precursor, it is generally considered safe at moderate doses. It is for research use only and not approved for clinical use.
|
| References |
|
| Additional Infomation |
2',4,4',6'-Tetrahydroxychalcone is a chalcone compound with the structure trans-chalcone, where hydroxyl groups are substituted at the 2', 4', 4', and 6' positions. It possesses metabolic, anti-allergic, and anti-inflammatory effects. It is a polyphenol belonging to the (E)-2'-hydroxychalcone class, and its function is related to that of trans-chalcone. Naringin chalcone has been reported to be found in hops, Sichuan poplar, and some other organisms with relevant data.
(E)-Naringenin chalcone is a research compound with potential applications in allergy, inflammation, and metabolic research. It is available as a reference standard for pharmacological studies. Its mechanism involves anti-allergic, antioxidant, and anti-inflammatory activities. No clinical trials or FDA approvals have been reported. |
| Molecular Formula |
C15H12O5
|
|---|---|
| Molecular Weight |
272.25
|
| Exact Mass |
272.068
|
| CAS # |
25515-46-2
|
| PubChem CID |
5280960
|
| Appearance |
Light yellow to yellow solid
|
| Density |
1.483±0.06 g/cm3(Predicted)
|
| Boiling Point |
538.7±50.0 °C(Predicted)
|
| Melting Point |
184 °C
|
| Source |
Originated from plants: Solanaceae Solanum lycopersicum L.
|
| LogP |
2.405
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
20
|
| Complexity |
347
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC1C=CC(/C=C/C(C2C(O)=CC(O)=CC=2O)=O)=CC=1
|
| InChi Key |
YQHMWTPYORBCMF-ZZXKWVIFSA-N
|
| InChi Code |
InChI=1S/C15H12O5/c16-10-4-1-9(2-5-10)3-6-12(18)15-13(19)7-11(17)8-14(15)20/h1-8,16-17,19-20H/b6-3+
|
| Chemical Name |
(E)-3-(4-hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)prop-2-en-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~183.7 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6731 mL | 18.3655 mL | 36.7309 mL | |
| 5 mM | 0.7346 mL | 3.6731 mL | 7.3462 mL | |
| 10 mM | 0.3673 mL | 1.8365 mL | 3.6731 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
